Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) COO Michael Hanley sold 2,104 shares of the company’s stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $26.82, for a total transaction of $56,429.28. Following the completion of the transaction, the chief operating officer directly owned 17,729 shares in the company, valued at approximately $475,491.78. The trade was a 10.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Jr. Michael Conick Hanley also recently made the following trade(s):
- On Wednesday, November 18th, Michael Hanley sold 2,896 shares of Alto Neuroscience stock. The stock was sold at an average price of $26.48, for a total value of $76,686.08.
- On Monday, November 16th, Michael Hanley sold 70,000 shares of Alto Neuroscience stock. The shares were sold at an average price of $27.68, for a total value of $1,937,600.00.
Alto Neuroscience Trading Down 4.5%
NYSE:ANRO opened at $25.32 on Friday. Alto Neuroscience, Inc. has a 52-week low of $12.51 and a 52-week high of $37.48. The stock has a fifty day moving average of $25.59 and a 200 day moving average of $24.89. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.12 and a quick ratio of 18.12.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.13. On average, equities analysts forecast that Alto Neuroscience, Inc. will post -2.48 EPS for the current fiscal year.
Hedge Funds Weigh In On Alto Neuroscience
Several institutional investors and hedge funds have recently made changes to their positions in ANRO. Commodore Capital LP raised its position in Alto Neuroscience by 49.4% in the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock worth $61,217,000 after purchasing an additional 900,000 shares during the period. Perceptive Advisors LLC boosted its position in Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after buying an additional 225,500 shares during the period. Spruce Street Capital LP boosted its position in Alto Neuroscience by 494.7% during the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after buying an additional 1,102,366 shares during the period. Bellevue Group AG purchased a new stake in Alto Neuroscience during the third quarter valued at about $29,706,000. Finally, Marshall Wace LLP boosted its position in Alto Neuroscience by 281.1% during the third quarter. Marshall Wace LLP now owns 859,309 shares of the company’s stock valued at $21,938,000 after buying an additional 633,806 shares during the period.
Wall Street Analyst Weigh In
ANRO has been the subject of several recent analyst reports. Zacks Research raised Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. BTIG Research reaffirmed a “buy” rating and issued a $37.00 target price on shares of Alto Neuroscience in a research note on Wednesday, November 11th. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a research note on Thursday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Tuesday, October 27th. Finally, Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.88.
View Our Latest Stock Report on ANRO
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.
Further Reading
- Five stocks we like better than Alto Neuroscience
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
